Literature DB >> 19531681

Tissue microarray validation: a methodologic study with special reference to lung cancer.

Christina Karlsson1, Lennart Bodin, Karin Piehl-Aulin, Mats G Karlsson.   

Abstract

BACKGROUND: Although tissue microarray (TMA) studies of histopathologic material have been frequently reported in studies of malignant diseases, the question of sample size (i.e., the diameter and the number of tissue cylinders investigated) has been rarely discussed. This study addresses the methodologic question of sample size in a variety of tumor types.
MATERIAL AND METHODS: Material from 29 cases of lung carcinoma (small cell, squamous cell, and adenocarcinomas) was examined immunohistochemically for Ki-67 and p53 expression in virtually constructed cylinders of different diameters. The influence of tissue sample size (i.e., different numbers of virtual cylinders) was also investigated. Results from Ki-67 evaluation were analyzed as a continuous variable, whereas p53 expression was scored. p53 evaluations based on scoring in cylinders versus scoring of whole sections were also compared. Furthermore, 10 cases of endometrial and breast carcinomas were evaluated for estrogen receptor, Ki-67, and HER2 by scoring up to five cylinders. RESULTS AND
CONCLUSIONS: Tissue cylinders of 0.6 and 1.0 mm diameters were compared and found equally informative about Ki-67 expression (intraclass correlation, 0.96). A statistical approach considering intraindividual and interindividual variation data is presented, indicating that in this specific setting three cylinders per case is an adequate sample size for TMA studies. Further sampling yields only a small gain in accuracy as determined by Ki-67 quantification and p53 scoring (kappa-coefficient, 0.9). For endometrial and breast tissues, TMA scoring of three cylinders yielded excellent agreement (kappa, >0.75) compared with whole-section scoring.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19531681     DOI: 10.1158/1055-9965.EPI-08-0743

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  4 in total

1.  Detecting EGFR alterations in clinical specimens-pitfalls and necessities.

Authors:  Sofi Isaksson; Pär-Ola Bendahl; Annette Salomonsson; Mats Jönsson; Monica Haglund; Alexander Gaber; Karin Jirström; Per Jönsson; Ake Borg; Leif Johansson; Johan Staaf; Maria Planck
Journal:  Virchows Arch       Date:  2013-10-26       Impact factor: 4.064

2.  Androgen receptor expression predicts breast cancer survival: the role of genetic and epigenetic events.

Authors:  Kate M Peters; Stacey L Edwards; Shalima S Nair; Juliet D French; Peter J Bailey; Kathryn Salkield; Sandra Stein; Sarah Wagner; Glenn D Francis; Susan J Clark; Melissa A Brown
Journal:  BMC Cancer       Date:  2012-04-02       Impact factor: 4.430

3.  Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections.

Authors:  Abir A Muftah; Mohammed A Aleskandarany; Methaq M Al-Kaabi; Sultan N Sonbul; Maria Diez-Rodriguez; Chris C Nolan; Carlos Caldas; Ian O Ellis; Emad A Rakha; Andrew R Green
Journal:  Breast Cancer Res Treat       Date:  2017-05-06       Impact factor: 4.872

4.  PD-L1 expression heterogeneity in non-small cell lung cancer: evaluation of small biopsies reliability.

Authors:  Enrico Munari; Giuseppe Zamboni; Marcella Marconi; Marco Sommaggio; Matteo Brunelli; Guido Martignoni; George J Netto; Francesca Moretta; Maria Cristina Mingari; Matteo Salgarello; Alberto Terzi; Vincenzo Picece; Carlo Pomari; Gianluigi Lunardi; Alberto Cavazza; Giulio Rossi; Lorenzo Moretta; Giuseppe Bogina
Journal:  Oncotarget       Date:  2017-10-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.